Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(37.5%)

Phase 1

2(25.0%)

Phase 3

2(25.0%)

Phase 2

1(12.5%)

8Total

N/A(3)

Phase 1(2)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05949775Not ApplicableNot Yet Recruiting

Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

Role: lead

NCT05911087Phase 2Unknown

A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2

Role: lead

NCT03908671Not ApplicableUnknown

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer

Role: lead

NCT05580159Phase 3Unknown

New Generation mRNA Booster Vaccine Against Emerging VOCs

Role: lead

NCT05686161Phase 3Unknown

mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs

Role: lead

NCT05144139Phase 1Completed

A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above

Role: lead

NCT05198752Phase 1Unknown

A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

Role: lead

NCT03468244Not ApplicableUnknown

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms

Role: collaborator

All 8 trials loaded